Immune cell proportions correlate with clinicogenomic features and ex vivo drug responses in acute myeloid leukemia

被引:1
|
作者
Romine, Kyle A. [1 ]
Bottomly, Daniel [1 ,2 ]
Yashar, William [1 ,3 ]
Long, Nicola [1 ,4 ]
Viehdorfer, Matthew [1 ]
McWeeney, Shannon K. [1 ,2 ]
Tyner, Jeffrey W. [1 ,5 ]
机构
[1] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97239 USA
[2] Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Div Bioinformat & Computat Biol, Portland, OR 97239 USA
[3] Oregon Hlth & Sci Univ, Sch Med, Portland, OR USA
[4] Oregon Hlth & Sci Univ, Dept Med, Div Hematol & Med Oncol, Portland, OR USA
[5] Oregon Hlth & Sci Univ, Dept Cell Dev & Canc Biol, Portland, OR 97239 USA
来源
FRONTIERS IN ONCOLOGY | 2023年 / 13卷
关键词
AML - acute myeloid leukemia; immune therapeutics; checkpoint inhibition therapy; RNAseq analysis; functional genomic data; REGULATORY T-CELLS; GROWTH-FACTOR; SUPPRESSION; RESISTANCE;
D O I
10.3389/fonc.2023.1192829
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: The implementation of small-molecule and immunotherapies in acute myeloid leukemia (AML) has been challenging due to genetic and epigenetic variability amongst patients. There are many potential mechanisms by which immune cells could influence small-molecule or immunotherapy responses, yet, this area remains understudied. Methods: Here we performed cell type enrichment analysis from over 560 AML patient bone marrow and peripheral blood samples from the Beat AML dataset to describe the functional immune landscape of AML. Results: We identify multiple cell types that significantly correlate with AML clinical and genetic features, and we also observe significant correlations of immune cell proportions with ex vivo small-molecule and immunotherapy responses. Additionally, we generated a signature of terminally exhausted T cells (Tex) and identified AML with high monocytic proportions as strongly correlating with increased proportions of these immunosuppressive T cells. Discussion: Our work, which is accessible through a new "Cell Type" module in our visualization platform (Vizome; http://vizome.org/), can be leveraged to investigate potential contributions of different immune cells on many facets of the biology of AML.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] Signaling mechanisms that regulate ex vivo survival of human acute myeloid leukemia initiating cells
    Bhavanasi, Dheeraj
    Wen, Kwun Wah
    Liu, Xiaolei
    Vergez, Francois
    Danet-Desnoyers, Gwenn
    Carroll, Martin
    Huang, Jian
    Klein, Peter S.
    [J]. BLOOD CANCER JOURNAL, 2017, 7
  • [42] Anticancer effects of Artemisia campestris extract on acute myeloid leukemia cells: an ex vivo study
    Kharrat, Rachid
    Ben Lakhal, Fatma
    Souia, Hiba
    Limam, Ines
    Ben Naji, Hend
    Abdelkarim, Mohamed
    [J]. MEDICAL ONCOLOGY, 2024, 41 (08)
  • [43] Effects of rapamycin on in vivo and ex vivo cell-mediated immune responses in cynomolgus monkeys
    Ancian, P.
    Grosdidier, E.
    Decheix-Nguyen, A.
    Sarlang, S.
    Descotes, J.
    [J]. TOXICOLOGY LETTERS, 2018, 295 : S86 - S87
  • [44] High-Throughput Functional Ex-Vivo Drug Testing and Multi-Omics Profiling in Patients with Acute Myeloid Leukemia
    Erkers, Tom
    Seashore-Ludlow, Brinton
    Struyf, Nona
    Marabita, Francesco
    James, Tojo
    Malani, Disha
    Vesterlund, Mattias
    Stalhl, Matthias
    Pawitan, Yudi
    Lehmann, Soren
    Ostling, Paivi
    Lehtio, Janne
    Kallioniemi, Olli
    [J]. BLOOD, 2019, 134
  • [45] Bortezomib enhances cytotoxicity of ex vivo-expanded gamma delta T cells against acute myeloid leukemia and T-cell acute lymphoblastic leukemia
    Story, Jamie Y.
    Zoine, Jaquelyn T.
    Burnham, Rebecca E.
    Hamilton, Jamie A. G.
    Spencer, H. Trent
    Doering, Christopher B.
    Raikar, Sunil S.
    [J]. CYTOTHERAPY, 2021, 23 (01) : 12 - 24
  • [46] Ex Vivo T Cell-Depleted versus Unmodified Allografts in Patients with Acute Myeloid Leukemia in First Complete Remission
    Bayraktar, Ulas D.
    de Lima, Marcos
    Saliba, Rima M.
    Maloy, Molly
    Castro-Malaspina, Hugo R.
    Chen, Julianne
    Rondon, Gabriela
    Chiattone, Alexander
    Jakubowski, Ann A.
    Boulad, Farid
    Kernan, Nancy A.
    O'Reilly, Richard J.
    Champlin, Richard E.
    Giralt, Sergio
    Andersson, Borje S.
    Papadopoulos, Esperanza B.
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2013, 19 (06) : 898 - 903
  • [47] Cell aggregation increases drug resistance of acute myeloid leukemia cells
    Fadeev R.S.
    Solovieva M.E.
    Slyadovskiy D.A.
    Zakharov S.G.
    Fadeeva I.S.
    Senotov A.S.
    Dolgikh N.V.
    Golenkov A.K.
    Akatov V.S.
    [J]. Biochemistry (Moscow) Supplement Series A: Membrane and Cell Biology, 2015, 9 (2) : 135 - 143
  • [48] CIRCULATING IMMUNE-COMPLEXES (CIC) CORRELATE WITH REMISSION DURATION IN ACUTE MYELOID-LEUKEMIA (AML)
    LUKIN, CL
    DALY, KM
    MICK, R
    GORE, S
    LEBEAU, MM
    LARSON, RA
    [J]. CLINICAL RESEARCH, 1989, 37 (04): : A916 - A916
  • [49] Cell Aggregation Increases Drug Resistance of Acute Myeloid Leukemia Cells
    Fadeev, R. S.
    Solovieva, M. E.
    Slyadovskiy, D. A.
    Zakharov, S. G.
    Fadeeva, I. S.
    Senotov, A. S.
    Dolgikh, N. V.
    Golenkov, A. K.
    Akatov, V. S.
    [J]. BIOLOGICHESKIE MEMBRANY, 2015, 32 (02): : 125 - 134
  • [50] Compromised anti-tumor-immune features of myeloid cell components in chronic myeloid leukemia patients
    Harada, Ibuki
    Sasaki, Haruka
    Murakami, Koichi
    Nishiyama, Akira
    Nakabayashi, Jun
    Ichino, Motohide
    Miyazaki, Takuya
    Kumagai, Ken
    Matsumoto, Kenji
    Hagihara, Maki
    Kawase, Wataru
    Tachibana, Takayoshi
    Tanaka, Masatsugu
    Saito, Tomoyuki
    Kanamori, Heiwa
    Fujita, Hiroyuki
    Fujisawa, Shin
    Nakajima, Hideaki
    Tamura, Tomohiko
    [J]. SCIENTIFIC REPORTS, 2021, 11 (01)